-
Study aim
-
To evaluate the therapeutic effects of a formulation containing Boswellia sacra, Zingiber officinale, Apium graveolens seeds, and Curcuma longa rhizome in patients with knee osteoarthritis.
-
Design
-
Two arm, parallel group, double blind, placebo controlled, randomized clinical trial with 88 participants, 1:1 allocation, conducted at a single center.
-
Settings and conduct
-
The study will be conducted at Imam Reza Hospital in Kermanshah, Iran. Eligible patients with knee osteoarthritis will be randomly assigned to the intervention or placebo group and followed for 90 days. Participants, care providers, investigators, and outcome assessors will be blinded to treatment allocation. Identical intervention and placebo tablets will be used to maintain blinding.
-
Participants/Inclusion and exclusion criteria
-
Adults aged 18 to 80 years with knee osteoarthritis will be included. Participants must have radiographic evidence of knee osteoarthritis and be willing to provide informed consent. Individuals with conditions or medication use that may interfere with the study intervention or outcomes will be excluded.
-
Intervention groups
-
Participants will be randomly allocated to two groups. The intervention group will receive one tablet daily containing Boswellia oleo gum resin 225 mg, ginger extract 60 mg, celery seed extract 91 mg, and turmeric rhizome extract 80 mg for 90 days. The control group will receive one identical placebo tablet daily for 90 days.
-
Main outcome variables
-
The primary outcome is the change in the Western Ontario and McMaster Universities Osteoarthritis Index score from baseline to day 90. Secondary outcomes include changes in inflammatory and oxidative stress biomarkers, including interleukin 6, interleukin 1 beta, tumor necrosis factor alpha, glutathione peroxidase, superoxide dismutase, vascular endothelial growth factor, and matrix metalloproteinases.